8
Oct
2024

Nanoform

Exhibitor at CPHI Milan 2024 stand 7G118, Contract Manufacturing and Services
About Us

Nanoform is an innovative nanoparticle medicine-enabling company that works together with global Pharma and biotech partners to devise solutions to complex formulation challenges. Nanoform’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) process can produce uniform nanoparticles as small as 10nm, facilitating transport even across biological barriers. As particles smaller than 100nm have significantly enhanced surface areas, this can increase drug dissolution rates and improve bioavailability, allowing drugs of poor solubility in the pharmaceutical pipeline...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 7G118, Contract Manufacturing and Services

Products Featured at CPHI Milan 2024

  • AI Drug Candidate Screening

    Product AI Drug Candidate Screening

    Our STARMAP® 2.0 platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered nanoforming and that exhibit optimal production characteristics.

    When existing data alone is not sufficient for generating specific pr...
  • Biologics

    Product Biologics

    Why have we developed our bio nanoparticle technology?

    The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes,...
  • Formulations

    Product Formulations

    We understand that speed is of the essence when working to deliver a life-changing drug to market. Our experienced clinical formulation development team can support formulation development across a vast range of dosage forms – including oral, ophthalmic and transdermal formulations, as well as injectables,...
  • Small Molecules

    Product Small Molecules

    Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.

    CESS® is a bottom-up method of recrystallization that wo...